A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
A Bispecific Antibody Targeting HER2 and HER3 Suppresses Tumor Growth
2018
Cancer Discovery
Preserved Fulltext
Précis: The FGFR1-3 inhibitor BGJ398 achieved responses with an acceptable safety profile in an expansion cohort of 67 patients with metastatic FGFR3-altered urothelial carcinoma .
doi:10.1158/2159-8290.cd-rw2018-087
pmid:29776909
fatcat:3qu3bbtfpfcmzcex27aojp2mhm